

3 July 2024
HUB24 Ltd (HUB): The platform of the future
We've initiated coverage on HUB24 (HUB), a specialist investment platform provider.

27 June 2024
Analyst Outlook June 2024
Our analysts provide their sector outlook and top stock picks for June 2024.

18 June 2024
Clinuvel Pharmaceuticals (CUV): Looking to Vitiligo
CUV are conducting two Phase 3 trials to expand the label of Scenesse to include patients with vitiligo.